Emiri T. Mandeville

Dr. Emiri T. Mandeville

Harvard Medical School, Massachusetts General Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2020 in Nature
Verified
Journal Article
Closed access
PDF file
EEElga Esposito
Elga Esposito
WLWenlu Li
Wenlu Li
Emiri T. MandevilleEmiri T. Mandeville
Emiri T. Mandeville
JPJi-Hyun Park
Ji-Hyun Park
IŞIkbal Şencan
Ikbal Şencan
ELEng Lo
Eng Lo

22 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
EEElga Esposito
Elga Esposito
BABum Ju Ahn
Bum Ju Ahn
JSJingfei Shi
Jingfei Shi
YNYoshihiko Nakamura
Yoshihiko Nakamura
JPJi Hyun Park
Ji Hyun Park
Kazuhide HayakawaKazuhide Hayakawa
Kazuhide Hayakawa
After stroke, peripheral immune cells are activated and these systemic responses may amplify brain damage, but how the injured brain sends out signals to trigger systemic inflammation remains unclear. Here we show that a brain-to-cervical lymph node (CLN) pathway is involved. In rats subjected to focal cerebral ischemia, lymphatic endothelial cells proliferate and macrophages are rapidly activated in CLNs within 24 h, in part via VEGF-C/VEGFR3 signalling. Microarray analyses of isolated lymphatic endothelium from CLNs of ischemic mice confirm the activation of transmembrane tyrosine kinase pathways. Blockade of VEGFR3 reduces lymphatic endothelial activation, decreases pro-inflammatory macrophages, and reduces brain infarction. In vitro, VEGF-C/VEGFR3 signalling in lymphatic endothelial cells enhances inflammatory responses in co-cultured macrophages. Lastly, surgical removal of CLNs in mice significantly reduces infarction after focal cerebral ischemia. These findings suggest that modulating the brain-to-CLN pathway may offer therapeutic opportunities to ameliorate systemic inflammation and brain injury after stroke.

21 July 2023 in Science
Verified
Journal Article
Closed access
AZAnqi Zhang
Anqi Zhang
Emiri T. MandevilleEmiri T. Mandeville
Emiri T. Mandeville
LXLijun Xu
Lijun Xu
CSCreed M. Stary
Creed M. Stary
ELEng Lo
Eng Lo
CLCharles Lieber
Charles Lieber
Implantable neuroelectronic interfaces have enabled advances in both fundamental research and treatment of neurological diseases but traditional intracranial depth electrodes require invasive surgery to place and can disrupt neural networks during implantation. We developed an ultrasmall and flexible endovascular neural probe that can be implanted into sub-100-micrometer–scale blood vessels in the brains of rodents without damaging the brain or vasculature. In vivo electrophysiology recording of local field potentials and single-unit spikes have been selectively achieved in the cortex and olfactory bulb. Histology analysis of the tissue interface showed minimal immune response and long-term stability. This platform technology can be readily extended as both research tools and medical devices for the detection and intervention of neurological diseases.

19 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
Wenlu LiWenlu Li
Wenlu Li
Emiri T. MandevilleEmiri T. Mandeville
Emiri T. Mandeville
VDVioleta Durán-Laforet
Violeta Durán-Laforet
NFNorito Fukuda
Norito Fukuda
ZYZhanyang Yu
Zhanyang Yu
ELEng Lo
Eng Lo
The concept of the neurovascular unit emphasizes the importance of cell-cell signaling between neural, glial, and vascular compartments. In neurogenesis, for example, brain endothelial cells play a key role by supplying trophic support to neural progenitors. Here, we describe a surprising phenomenon where brain endothelial cells may release trans-differentiation signals that convert astrocytes into neural progenitor cells in male mice after stroke. After oxygen-glucose deprivation, brain endothelial cells release microvesicles containing pro-neural factor Ascl1 that enter into astrocytes to induce their trans-differentiation into neural progenitors. In mouse models of focal cerebral ischemia, Ascl1 is upregulated in endothelium prior to astrocytic conversion into neural progenitor cells. Injecting brain endothelial-derived microvesicles amplifies the process of astrocyte trans-differentiation. Endothelial-specific overexpression of Ascl1 increases the local conversion of astrocytes into neural progenitors and improves behavioral recovery. Our findings describe an unexpected vascular-regulated mechanism of neuroplasticity that may open up therapeutic opportunities for improving outcomes after stroke.

1 July 2024 in Stroke
Verified
Journal Article
Closed access
HAHong An
Hong An
BZBing Zhou
Bing Zhou
Kazuhide HayakawaKazuhide Hayakawa
Kazuhide Hayakawa
VLVioleta Duran Laforet
Violeta Duran Laforet
JPJi-Hyun Park
Ji-Hyun Park
Xunming JiXunming Ji
Xunming Ji
BACKGROUND: The mitochondrial unfolded protein response (UPR mt ) is an evolutionarily conserved mitochondrial response that is critical for maintaining mitochondrial and energetic homeostasis under cellular stress after tissue injury and disease. Here, we ask whether UPR mt may be a potential therapeutic target for ischemic stroke. METHODS: We performed the middle cerebral artery occlusion and oxygen-glucose deprivation models to mimic ischemic stroke in vivo and in vitro, respectively. Oligomycin and meclizine were used to trigger the UPR mt . We used 2,3,5-triphenyltetrazolium chloride staining, behavioral tests, and Nissl staining to evaluate cerebral injury in vivo. The Cell Counting Kit-8 assay and the Calcein AM Assay Kit were conducted to test cerebral injury in vitro. RESULTS: Inducing UPR mt with oligomycin protected neuronal cultures against oxygen-glucose deprivation. UPR mt could also be triggered with meclizine, and this Food and Drug Administration-approved drug also protected neurons against oxygen-glucose deprivation. Blocking UPR mt with siRNA against activating transcription factor 5 eliminated the neuroprotective effects of meclizine. In a mouse model of focal cerebral ischemia, pretreatment with meclizine was able to induce UPR mt in vivo, which reduced infarction and improved neurological outcomes. CONCLUSIONS: These findings suggest that the UPR mt is important in maintaining the survival of neurons facing ischemic/hypoxic stress. The UPR mt mechanism may provide a new therapeutic avenue for ischemic stroke.

Verified
Journal Article
Open access
PDF file
JSJi Hae Seo
Ji Hae Seo
TMTakakuni Maki
Takakuni Maki
NMNobukazu Miyamoto
Nobukazu Miyamoto
YCYoon Kyung Choi
Yoon Kyung Choi
KCKelly K. Chung
Kelly K. Chung
KAKen Arai
Ken Arai
A-kinase anchor protein 12 (AKAP12) is a scaffolding protein that associates with intracellular molecules to regulate multiple signal transductions. Although the roles of AKAP12 in the central nervous system are still relatively understudied, it was previously shown that AKAP12 regulates blood-retinal barrier formation. In this study, we asked whether AKAP12 also supports the function and integrity of the blood-brain barrier (BBB). In a mouse model of focal ischemia, the expression level of AKAP12 in cerebral endothelial cells was upregulated during the acute phase of stroke. Also, in cultured cerebral endothelial cells, oxygen-glucose deprivation induced the upregulation of AKAP12. When AKAP12 expression was suppressed by an siRNA approach in cultured endothelial cells, endothelial permeability was increased along with the dysregulation of ZO-1/Claudin 5 expression. In addition, the loss of AKAP12 expression caused an upregulation/activation of the Rho kinase pathway, and treatment of Rho kinase inhibitor Y-27632 mitigated the increase of endothelial permeability in AKAP12-deficient endothelial cell cultures. These in vitro findings were confirmed by our in vivo experiments using Akap12 knockout mice. Compared to wild-type mice, Akap12 knockout mice showed a larger extent of BBB damage after stroke. However, the inhibition of rho kinase by Y-27632 tightened the BBB in Akap12 knockout mice. These data may suggest that endogenous AKAP12 works to alleviate the damage and dysfunction of the BBB caused by ischemic stress. Therefore, the AKAP12-rho-kinase signaling pathway represents a novel therapeutic target for stroke.